-

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 94 employees covering an aggregate of 158,197 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company’s 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to the employee’s continued service through each applicable vesting date.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Contacts

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:

Allison Marshall
amarshall@castlebiosciences.com

Castle Biosciences Inc.

NASDAQ:CSTL

Release Summary
Castle Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4).
Release Versions
$Cashtags

Contacts

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:

Allison Marshall
amarshall@castlebiosciences.com

Social Media Profiles
More News From Castle Biosciences Inc.

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting....

Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), today announced its financial results for the fourth quarter and year ended December 31, 2024....

Castle Biosciences to Participate in Upcoming Investor Conferences

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences' executive management is scheduled to present a company overview at two investor conferences next month....
Back to Newsroom